Improving the railway construction industry by collecting data to reduce inefficiencies and overspending. Rail Diary is a B2B SaaS product that is designed to analyse information on infrastructure projects to improve particular elements that plague the industry. These include the delivery, commercialisation and the health and safety of projects.
Rail Diary allows developers to monitor ongoing costs, forecast for the future and reduce the number of claims made. Rail Diary will generate revenue via a monthly subscription model ranging from £45 to £150, plus project fees.
days to go:
Expired
investment:
£50,544
Nayanacare is a mobile and pc app that allows individual customers to make the right choice of care services and carers quick and easy. Care suppliers can reduce costs by using Nayanacare as a dedicated marketing platform and take advantage of the platforms business management capabilities.
days to go:
Expired
investment:
£76,030
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.
days to go:
Expired
investment:
£211,595
Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.
days to go:
Expired
investment:
£134,892
Jupiter Diagnostics provide a patent-protected portable reader and test card to provide reliable and cost-effective blood results. Each test card has the ability to measure multiple tests from a prick of blood from the finger and can deliver laboratory-quality results in just ten minutes.
days to go:
Expired
investment:
£2,005,050
Cornish Lithium intends to set up an environmentally-responsible and unique lithium extraction industry in the UK. The company has acquired exploration rights for lithium and other battery metals across Cornwall. Extensive mineral rights agreements have given the company a first-mover advantage in Cornwall. The funds raised will be used to support research over the next 12 months, which includes sample collection, in order to completely understand the battery metal potential of Cornwall.
days to go:
Expired
investment:
£1,430,640
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.
days to go:
Expired
investment:
Withheld
Molecular Warehouse are trying to create a world where most diseases are prevented by giving people the chance to monitor and manage their helath where ever and whenever. Molecular Warehouse have developed a platform that allows anyone to test themselves at any time.
days to go:
Expired
investment:
£737,480
INSPHERE uses image sensors and Artificial Intelligence (AI) to guide and correct robot positioning during the manufacturing process, ensuring right-first-time production. The company argues that industrial robots are not completely accurate and can experience unplanned downtime that can cost up to £10,000 per minute. INSPHERE asserts that its solution allows factory operators to operate safely with less downtime, and with multiple robot and human operators. The company has developed three products since 2013 which have received recognition in the aerospace and industrial automation sectors. INSPHERE is now launching IONA, a network of sensors that can be permanently deployed in a manufacturing environment to monitor and control industrial robots. IONA, the company points out, uses both hardware and software to correct errors taking into account the robot and its relationship to the workpiece. INSPHERE will use the investment to diversify the reach of IONA across markets.
days to go:
Expired
investment:
£1,149,999
Carnot is developing hydrogen engines with key components manufactured from ceramics able to withstand fuel combustion temperatures, eliminating the need for cooling systems and doubling the efficiencies of modern engines. The company argues that modern engines waste on average one-third of fuel energy to cool systems that stop metallic components from melting. Carnot claims that its engines eliminate this waste doubling efficiency, halve fuel costs and CO2 and achieve net-zero operation by operating on biofuels and hydrogen benefiting the long haul transport, marine and primary off-grid power markets. Carnot has raised over £600,000 including a pre-seed round in 2020 for £357,000 at a pre-money valuation of £2 million, a £300,000 Innovate UK grant and another £300,000 Eureka Eurostar’s grant. Carnot has a 5-year, 3-phase exit strategy and will begin licensing its IP at the end of 2023 at which point it will begin generating revenue. It will eventually look for acquisition from one of its manufacturing partners in 2025 after demonstrating industry acceptance of its technology.
days to go:
Expired
investment:
£262,500
